November 05, 2025

SGLT2 Inhibitors Reduce Lung Cancer Surgery

Patients with diabetes taking SGLT2 inhibitors show fewer lung surgeries over 10 years.

Conexiant

November 04, 2025

New Poll: Only 1 in 3 Link Alcohol to Cancer

“Individuals who drink alcohol were more likely to believe that alcohol consumption has no effect on cancer risk, which is alarming, given the growing burden of alcohol-related cancers in the United States."

Conexiant

October 29, 2025

H-1B Visa Changes: Who Pays the Price?

New fee structure could hit hardest where physicians are needed most.

Conexiant

October 21, 2025

Can Cancer Bring America Together?

At a time of deep division, cancer survivors from across the political spectrum unite in Washington to demand action on research and care.

KFF Health News

October 15, 2025

Medical Oddities: The Half-Hour Health Hack

Metabolic tweaks, sensory sweet spots, antiviral spice, and a soothing cup for the heart and more this week.

Conexiant

October 08, 2025

Risk vs. Benefit: Clinical Trial Aims to Identify Patients with Early-Stage NSCLC Who May Not Need Immunotherapy After Surgery

Many patients with early-stage non-small cell lung cancer (NSCLC) are treated post-surgery with the monoclonal antibody durvalumab (brand name Imfinzi) — an FDA-approved regimen.

Roswell Park Comprehensive Cancer Center

August 27, 2025

FDA Approves LP.8.1 COVID-19 Vaccines

LP.8.1-targeted COVID-19 vaccines for adults 65 and older and higher-risk patients were approved by the US Food and Drug Administration.

Conexiant

August 09, 2023

Adjuvant Osimertinib in Resected EGFR-Mutant NSCLC: Overall Survival Analysis of the ADAURA Trial

As reported in The New England Journal of Medicine by Masahiro Tsuboi, MD, and colleagues, the planned final overall survival analysis of the phase III ADAURA trial has shown a significant benefit wit...

The ASCO Post

September 21, 2023

NeoCOAST: Durvalumab Monotherapy vs Combined With Other Immunotherapies for Early-Stage NSCLC

An anti–PD-L1 monoclonal antibody in combination with other immuno-oncology agents may outperform treatment with the agent on its own in the neoadjuvant setting for patients with early-stage non–small...

The ASCO Post